PEDIATRICS Vol. 72 No. 4 October 1983, pp. 491-499
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, R. J.
Right arrow Articles by Snider, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, R. J.
Right arrow Articles by Snider, D. E., Jr

Hepatotoxicity from Isoniazid and Rifampin Among Children Treated for Tuberculosis

Richard J. O'Brien MD1, Mary W. Long MA1, Floy S. Cross BA1, Mary Anne Lyle 1, and Dixie E. Snider Jr MD1

1 From the Tuberculosis Control Division, Center for Prevention Services, Centers for Disease Control, Public Health Service, Department of Health and Human Services, Atlanta

To estimate rates of hepatotoxicity in the United States among children treated for tuberculosis, we conducted a retrospective survey of health departments and individual practitioners. We received 874 reports suitable for analysis of children treated during 1977 to 1979. A total of 16 hepatotoxic reactions were reported; 14/430 (3.3%) children receiving isoniazid and rifampin had a hepatotoxic reaction, which approximates the rate seen in adults taking these drugs. Half of the reactions occurred during the first month of therapy, and all of the well-documented reactions were noted during the first 10 weeks. Because the likelihood of hepatotoxicity may be increased with higher drug doses, limiting the dose of isoniazid to 10 mg/kg and that of rifampin to 15 mg/kg may help minimize hepatotoxic reactions. Because more serious disease, especially disseminated tuberculosis, may further increase the risk of hepatotoxicity, close monitoring of such children receiving isoniazid and rifampin should help minimize serious hepatotoxicity. Routine biochemical monitoring may not be necessary for all children, eg, those with mild forms of disease and those with normal pretreatment liver function who are treated with lower drug doses.

Key Words: tuberculosis • isoniazid • rifampin • short-course chemotherapy • drug-induced hepatotoxicity

Accepted on December 22, 1982




This article has been cited by other articles:


Home page
 PediatricsHome page
V. J. Flaherman, T. C. Porco, E. Marseille, and S. E. Royce
Cost-effectiveness of Alternative Strategies for Tuberculosis Screening Before Kindergarten Entry
Pediatrics, July 1, 2007; 120(1): 90 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al.
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999.
Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247.
[Full Text] [PDF]